Tumour volume and radiotherapy prolongation in locally advanced head and neck cancer patients treated with radical IMRT.
IMRT
head and neck cancer
local control
radiotherapy treatment time
survival
tumour volume
Journal
Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
ISSN: 1804-7521
Titre abrégé: Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
Pays: Czech Republic
ID NLM: 101140142
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
29
05
2021
accepted:
13
07
2021
pubmed:
10
9
2021
medline:
16
12
2022
entrez:
9
9
2021
Statut:
ppublish
Résumé
The relationship of tumour volume, radiotherapy treatment time and other prognostic factors affecting prognosis was evaluated. 184 patients with locally advanced head and neck cancer were treated with radical intensity modulated radiotherapy (IMRT) and compared retrospectively. In the multivariate analysis the overall survival was dependent on gross tumour volume (GTV), clinical stage (CS), radiotherapy treatment time (RTT) and p16 status. Local control was influenced by GTV, overall RTT and age. DFS was significantly affected by GTV, CS, RTT, p16 status and concomitant chemotherapy (CHT). The tumour volume and the radiotherapy treatment time were the most significant prognostic factors with the best outcomes in patients with GTV ≤ 55 cc and RTT ≤ 48 days (mean LC 8.1, DFS 7.1 and OS 6.4 years) and worst outcomes with GTV > 55 cc and RTT >48 days (mean LC 4.4, mean DFS 3.2 and mean OS 2.6 years).
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
405-411Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Joiner MC, van der Kogel A: Basic Clinical Radiobiology, 5th Edition, 2019, CRC Press/Taylor&Francis Group, ISBN 9780429490606.
doi: 10.1201/9780429490606
Hendry JH, Bentzen SM, Dale RG, Fowler JF, Wheldon TE, Jones B, Munro AJ, Slevin NJ, Robertson AG: A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol 1996,8(5):297-307.
doi: 10.1016/S0936-6555(05)80715-0
Kurek R, Kalogera-Fountzila A, Muskalla K, Dafni U, Schnabel T, Kober B, Röddiger S, Martin T, Fountzilas G, Zamboglou N. Usefulness of tumor volumetry as a prognostic factor of survival in head and neck cancer. Strahlenther Oncol 2003;179:292-97.
doi: 10.1007/s00066-003-1017-0
Johnson CR, Khandelwal SR, Schmidt-Ullrich RK, Ravalese J 3rd, Wazer DE. The influence of quantitative tumor volume measurements on local control in advanced head and neck cancer using concomitant boost accelerated superfractionated irradiation. Int J Radiat Oncol Biol Phys 1995;32:635-41.
doi: 10.1016/0360-3016(95)00031-S
Cvek J, Knybel L, Stránský J, Matoušek P, Res O, Zeleník K, Otáhal B, Molenda L, Skácelíková E, Stieberová N, Čermáková Z, Feltl D. Intensity Modulated Hyperfractionated Accelerated Radiotherapy to Treat Advanced Head and Neck Cancer - Predictive Factors of Overall Survival. Klin Onkol 2017;30(4):282-88.
pubmed: 28832174
doi: 10.14735/amko2017282
Rudat V, Dietz A, Schramm O, Conradt C, Maier H, Flentje M, Wannenmacher M. Prognostic impact of total tumor volume and haemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol 1999;53:119-25.
doi: 10.1016/S0167-8140(99)00149-8
Grabenbauer GG, Steininger H, Meyer M, Fietkau R, Brunner T, Heinkelmann P, Hornung J, Iro H, Spitzer W, Kirchner T, Sauer R, Distel L. Nodal CT density and tumor volume as prognostic factors after radiation therapy of stage III/IV head and neck cancer. Radiother Oncol 1998;47:175-83.
doi: 10.1016/S0167-8140(98)00016-4
Studer G, Lütolf UM, El-Bassiouni M, Rousson V, Glanzmann C. Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT. Acta Oncol 2007;46(3):386-94.
doi: 10.1080/02841860600815407
Dunst J, Stadler P, Becker A, Lautenschläger C, Pelz T, Hänsgen G, Molls M, Kuhnt T. Tumor volume and tumor hypoxia in head and neck cancers. The amount of the hypoxic volume is important. Strahlenther Onkol 2003;179(8):521-26.
pubmed: 14509950
doi: 10.1007/s00066-003-1066-4
Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41(1):31-39.
doi: 10.1016/S0167-8140(96)91811-3
Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38(2):285-89.
doi: 10.1016/S0360-3016(02)03551-4
Vaupel P. Blood flow and oxygenation status of head and neck carcinomas. Adv Exp Med Biol 1997;428:89-95.
doi: 10.1007/978-1-4615-5399-1_13
Toustrup K, Sørensen BS, Alsner J, Overgaard J. Hypoxia gene expression signatures as prognostic and predictive markers in head and neck radiotherapy. Semin Radiat Oncol 2012;22(2):119-27.
doi: 10.1016/j.semradonc.2011.12.006
Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000;76(5):589-605.
doi: 10.1080/095530000138259
Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 2003;195(1):1-16.
doi: 10.1016/S0304-3835(03)00012-0
Höckel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001;93(4):266-76.
doi: 10.1093/jnci/93.4.266
Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007;26:225-39.
pubmed: 17440684
doi: 10.1007/s10555-007-9055-1
Overgaard J. Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007;25(26):4066-74.
doi: 10.1200/JCO.2007.12.7878
Hoff CM, Grau C, Overgaard J. Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma-a prospective study. Radiother Oncol 2012;103(1):38-44.
doi: 10.1016/j.radonc.2012.01.011
Jirkovska M, Novak T, Malinova B, Lohynska R. Three-dimensional conformal radiotherapy versus intensity modulated radiotherapy with simultaneous integrated boost in the treatment of locally advanced head and neck carcinoma. Neoplasma 2019;66(5):830-38.
doi: 10.4149/neo_2018_181209N941
Duncan W, MacDougall RH, Kerr GR, Downing D. Adverse effect of treatment gaps in the outcome of radiotherapy for laryngeal cancer. Radiother Oncol 1996;41(3):203-7.
doi: 10.1016/S0167-8140(96)01838-5
Lohynska R, Slavicek A, Bahanan A, Novakova P. Predictors of local failure in early laryngeal cancer. Neoplasma 2005;52(6):483-88.
pubmed: 16284693
Dahlke S, Steinmann D, Christiansen H, Durisin M, Eckardt A, Wegener G, Bremer M, Meyer A. Impact of Time Factors on Outcome in Patients with Head and Neck Cancer Treated with Definitive Radio(Chemo)Therapy. In Vivo 2017;31(5):949-55.
pubmed: 28882964
doi: 10.21873/invivo.11152
Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 2014;32(34):3858-66.
doi: 10.1200/JCO.2014.55.3925
Gupta T, Agarwal J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S, Murthy V, Budrukkar A, Dinshaw K, Prabhash K, Chaturvedi P, D'Cruz A. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. Radiother Oncol 2012;104(3):343-48.
pubmed: 22853852
doi: 10.1016/j.radonc.2012.07.001
Ghosh-Laskar S, Yathiraj PH, Dutta D, Rangarajan V, Purandare N, Gupta T, Budrukkar A, Murthy V, Kannan S, Agarwal JP. Prospective randomized controlled trial to compare 3-dimensional conformal radiotherapy to intensity-modulated radiotherapy in head and neck squamous cell carcinoma: Long-term results. Head Neck 2016;38 Suppl 1:E1481-E1487.
pubmed: 26561342
doi: 10.1002/hed.24263
Plataniotis GA, Theofanopoulou ME, Kalogera-Fountzila A, Haritanti A, Ciuleanou E, Ghilezan N, Zamboglou N, Dimitriadis A, Sofroniadis I, Fountzilas G. Prognostic impact of tumor volumetry in patients with locally advanced head-and-neck carcinoma (non-nasopharyngeal) treated by radiotherapy alone or combined radiochemotherapy in a randomized trial. Int J Radiat Oncol Biol Phys 2004;59(4):1018-26.
pubmed: 15234035
doi: 10.1016/j.ijrobp.2004.01.021
Chao KS, Ozyigit G, Blanco AI, Thorstad WL, Deasy JO. Intensity-modulated radiation therapy for oropharyngeal carcinoma: Impact of tumor volume. Int J Radiat Oncol Biol Phys 2004;59:43-50.
pubmed: 15093897
doi: 10.1016/j.ijrobp.2003.08.004
Romesser PB, Qureshi MM, Subramaniam RM, Sakai O, Jalisi S, Truong MT. A prognostic volumetric threshold of gross tumor volume in head and neck cancer patients treated with radiotherapy. Am J Clin Oncol 2014;37(2):154-61.
doi: 10.1097/COC.0b013e31826e04d6
Slavik M, Kazda T, Selingerová I, Šána J, Ahmad P, Gurín D, Hermanová M, Novotný T, Červená R, Dymáčková R, Burkoň P, Slabý O, Šlampa P. Effect of Tumor Size and p16 Status on Treatment Outcomes - Achievement of Complete Remission in Prospectively Followed Patients with Oropharyngeal Tumors. Klin Onkol 2019;32(1):58-65.
pubmed: 30764631
doi: 10.14735/amko201958
Pytynia KB, Dahlstrom KR, Sturgis EM. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol 2014;50(5):380-86.
doi: 10.1016/j.oraloncology.2013.12.019
Lassen P, Lacas B, Pignon JP, Trotti A, Zackrisson B, Zhang Q, Overgaard J, Blanchard P; MARCH Collaborative Group. Prognostic impact of HPV-associated p16-expression and smoking status on outcomes following radiotherapy for oropharyngeal cancer: The MARCH-HPV project. Radiother Oncol 2018;126(1):107-15.
pubmed: 29100700
doi: 10.1016/j.radonc.2017.10.018
You EL, Henry M, Zeitouni AG: Human papillomavirus-associated oropharyngeal cancer: review of current evidence and management. Curr Oncol 2019;26(2):119-23.
pubmed: 31043814
doi: 10.3747/co.26.4819
Schofield CP, Sykes AJ, Slevin NJ, Rashid NZ. Radiotherapy for head and neck cancer in elderly patients. Radiother Oncol 2003;69(1):37-42.
pubmed: 14597355
doi: 10.1016/S0167-8140(03)00249-4
Roennegaard AB, Rosenberg T, Bjørndal K, Sørensen JA, Johansen J, Godballe C. The Danish Head and Neck Cancer fast-track program: a tertiary cancer centre experience. Eur J Cancer 2018;90:133-39.
pubmed: 29273285
doi: 10.1016/j.ejca.2017.10.038
Panek R, Welsh L, Baker LCJ, Schmidt MA, Wong KH, Riddell AM, Koh DM, Dunlop A, Mcquaid D, d'Arcy JA, Bhide SA, Harrington KJ, Nutting CM, Hopkinson G, Richardson C, Box C, Eccles SA, Leach MO, Robinson SP, Newbold KL. Noninvasive Imaging of Cycling Hypoxia in Head and Neck Cancer Using Intrinsic Susceptibility MRI. Clin Cancer Res 2017;23(15):4233-41.
doi: 10.1158/1078-0432.CCR-16-1209
Stieb S, Eleftheriou A, Warnock G, Guckenberger M, Riesterer O. Longitudinal PET imaging of tumor hypoxia during the course of radiotherapy. Eur J Nucl Med Mol Imaging 2018;45(12):2201-17.
doi: 10.1007/s00259-018-4116-y
Halmos GB, Bruine de Bruin L, Langendijk JA, van der Laan BF, Pruim J, Steenbakkers RJ. Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside (18F-FAZA)-PET: a review. Clin Nucl Med 2014;39(1):44-8.
pubmed: 24152663
doi: 10.1097/RLU.0000000000000286
Carpén T, Saarilahti K, Haglund C, Markkola A, Tarkkanen J, Hagström J, Mattila P, Mäkitie A. Tumor volume as a prognostic marker in p16-positive and p16-negative oropharyngeal cancer patients treated with definitive intensity-modulated radiotherapy. Tumorvolumen als prognostischer Marker bei p16-positiven und p16-negativen Patienten mit Oropharyngealkarzinom unter Therapie mit definitiver intensitätsmodulierter Strahlentherapie. Strahlenther Onkol 2018;194(8):759-70.
pubmed: 29774396
doi: 10.1007/s00066-018-1309-z